Cannabinoid Pharmaceutical Company

The Company has developed a defendable patent estate around their novel cannabinoid & terpene compounding process, along with successful prototype formulations, and methods of administering the formulations. They are committed to improving cancer treatment standard of care; originally focused on palliative until proof of concept studies established synergies with multiple chemotherapies.

The data provides an FDA pathway to improve cancer patient treatment outcomes. In addition, several in-house case studies have demonstrated efficacy with multiple neurological disorders. The Company has pre-clinical in-vitro & in-vivo results from a leading cancer treatment hospital demonstrating that their prototype formulation is safe, more effective than CBD alone, and works synergistically with current standard of care chemotherapies by both killing more cancer and by reducing the adverse effects patients experience from the traditional treatment. Thus, it could be added to standard regimens; allowing physicians to better utilize/maximize current treatment modalities.

The Company and their high caliber team are pursuing acquisition by an acquirer with the right sales, distribution, and validation in place to quickly take optimized formulations to market. Their goal is to have the most immediate and life-saving impact, to establish the long-term legacy of improved standard of care across multiple indications via non-psychotropic cannabinoid-based treatments.